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Now a days there are several medical device products available for us. 
We might not know that we are using medical devices, since those are 
sometimes so close to medicines. The definition for medical devices is 
‘Any instrument, apparatus, appliance, material or other article, whether 
used alone or in combination, together with any accessories or software 
for its proper functioning, intended by the manufacturer to be used for 
human beings in the: 1) Diagnosis, prevention, monitoring, treatment or 
alleviation of disease, injury or handicap, 2) Investigation, replacement or 
modification of the anatomy or of a physiological process, or 3) Control 
of conception, and which does not achieve its principal intended action in 
or on the human body by pharmacological, immunological or metabolic 
means, but which may be assisted in its function by such mean’[1]. It 
is easy to understand that heart or hip implant is a medical device, but 
there are products like the macrogol products used for stomach function 
and eye drops for dry eyes that can be registered as a medical device, 
too. These products can be registered either as medicines or medical 
devices depending the decision made by the company. On the other hand, 
bioactive glass used for e.g. as a bone filler is classified as a medical device 
[2]. In Europe this means that all these products are so called CE-marked 
products and have market authorisation in Europe. Basically, this means 
that any substance having no pharmacological effect, but may have effect 
to body function, is medical device.
Even if these products have no pharmacological effect, they must be 
safe and effective. Moreover, these products have huge opportunity for us 
in several ways. First as combination products, combining the medical 
device function and medicine together in order to get best result in 
the treatment of the disease e.g., bioactive glass and antibiotic-loaded 
calcium-based bone substitutes in the treatment of chronic osteomyelitis 
[3]. Another great opportunity offered for us is that we can use the medical 
device as the carrier for the APIs or even enhance the effect of the API, as 
described in our previous study with clodronate and bioactive glass [4,5].
These combination products are really challenging e.g., for those taking 
care of design, development, market authorisation and regulatory aspects 
since the product should fulfil the both demands and legislations, those 
of a drug and those for a medical device. This sometimes causes for the 
company the building of double quality systems, but when being clever 
a clear synergy between these two can be obtained to the benefit of the 
product and the patient using the product.
Very little academic research is done on the regulatory aspects of 
medical devices in the interface of pharmaceuticals. Therefore, it is crucial 
to investigate what strategic decisions the pharmaceutical companies 
are facing while making decisions, which way to go, to get the market 
authorisation as a pharmaceutical product or build up the quality system 
for a medical device. The work load for medical device registration may be 
much less than that of pharmaceuticals especially in class I and II medical 
devices. However, from the marketing point, it can be beneficial to have the 
product as a pharmaceutical product. Therefore, it would be important to 
study how the registration process and the life cycle management of these 
two options are differing from the pragmatic point of view. Further, it is 
essential to investigate the resources needed in the registration processes: 
FTEs of the staff, their use of time and the effect on their work description. 
This information would also help the companies in their decision making 
in future and give the regulatory bodies valuable information on what 
demands of resources and challenges the current regulations are causing.
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